Amicus Therapeutics, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 151.58 million compared to USD 236.57 million a year ago. Basic loss per share from continuing operations was USD 0.51 compared to USD 0.82 a year ago.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
9.315 USD | +3.04% | -10.68% | -34.41% |
01:24pm | Guggenheim Upgrades Amicus Therapeutics to Buy From Neutral With $13 Price Target | MT |
05-10 | UBS Trims Price Target on Amicus Therapeutics to $19 From $20, Keeps Buy Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-34.41% | 2.68B | |
+28.44% | 48.16B | |
-1.09% | 41.73B | |
+43.45% | 41.03B | |
-5.26% | 28.77B | |
+10.14% | 25.59B | |
-22.80% | 18.96B | |
+8.13% | 12.92B | |
+28.76% | 12.03B | |
-1.92% | 11.77B |
- Stock Market
- Equities
- FOLD Stock
- News Amicus Therapeutics, Inc.
- Amicus Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023